InflaRx N.V. (IFRX)
NASDAQ: IFRX · Real-Time Price · USD
2.430
-0.040 (-1.62%)
Jan 22, 2025, 3:32 PM EST - Market open
InflaRx Employees
InflaRx had 62 employees as of December 31, 2023. The number of employees increased by 18 or 40.41% compared to the previous year.
Employees
62
Change (1Y)
18
Growth (1Y)
40.41%
Revenue / Employee
$3,021
Profits / Employee
-$1,019,980
Market Cap
143.09M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
IFRX News
- 7 days ago - InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS) - GlobeNewsWire
- 4 weeks ago - InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904 - GlobeNewsWire
- 2 months ago - InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome - GlobeNewsWire
- 2 months ago - InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 4 months ago - InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology Congress - GlobeNewsWire
- 5 months ago - InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases - GlobeNewsWire
- 5 months ago - InflaRx Announces Participation in September Investor Events - GlobeNewsWire
- 5 months ago - InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire